Skip to main content
Equibles

UPC · Universe Pharmaceuticals INC

Track UPC — free

Use UPC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research UPC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.10 +0.55 (+15.49%)
Rebalance outlook locked
Market Cap
$19.34M
Shares
5.02M
Volume · Oct 21 155.59K Avg daily vol (3M) 761.95K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.55 Open$3.72 Day$3.34–3.72 52W close$2.25–12.18 Avg vol 30d46K Short int44K · 0.9% float · 1.1d Short vol53% DataMar 2021–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$17.86B
Trailing 12 months
Net income (TTM)
−$3.67B
Trailing 12 months
Revenue growth YoY
-22.4%
Year over year
Operating margin
-16.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-30,287.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3,174.9%
Year over year · more shares
Price change (1Y)
-24.9%
Trailing year
Short interest
0.9%
Latest settlement · 1.1 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg −24%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 13%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −24%
trailing
6-month return +10%
trailing
YTD return −7%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.87% of float · ▼ -42.2% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
4 holders — mid 3-yr range
Squeeze score 36
low risk · 0–100
Fundamentals
Fair
Revenue growth −22%
Y/Y
Gross margin 35%
expanding
EPS growth +99%
Y/Y
Free cash flow $-5.3B
Quant / Vol
risk profile
Very High
Volatility 349%
annualized · 1-yr
Max drawdown −74%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
−24% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
13% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.87% of float · ▼ -42.2% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
4 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $4 · 13% Range high $12
vs 200-day avg -8% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
UPC
Universe Pharmaceuticals INC
this stock
$19.34M -6.8% -22.4% — 0.9%
TAK
Takeda Pharmaceutical Co Ltd
 $64.15B +28.8% — — 0.1%
GALDY
Galderma Group AG
 $48.88B +2.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $46.21B +30.9% +4.3% 65.0 2.6%
HLN
Haleon plc
 $44.72B +0.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
4
% held
0.7%
Net QoQ
+37.5K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
43.9K
Days to cover
1.1d
Change
-32.0K sh
View
Short Volume
Short vol %
53%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$5
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
14.1%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$17.9B
Net income (FY)
$-3.7B
EPS diluted
$-8.06
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 6, 2026
This year
10
View

Performance

5D 20D 120D MTD YTD
UPC -16.9% -23.9% +9.9% -17.4% -6.8%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -15.7% -23.3% +1.8% -18.3% -19.6%
Key facts CIK 1809616 CUSIP G9442G138